Market Access Reuters Europe 2025: Using value propositions to improve acc... In a Reuters Pharma Europe 2025 fireside chat, NICE Advice Director Brad Grove spoke with Novartis's Matic Meglic about novel pharma payment models.
Market Access Reuters Europe 2025: Trade-offs in European launch sequencin... At Reuters, industry stakeholders discussed how, especially in light of the current tariff crisis, Europe must operate as a unit when pricing drugs.
Market Access Reuters Europe 2025: Collaboration key for innovation, BI he... At Reuters Pharma Europe, Francesco Di Marco of Boehringer Ingelheim focused on the importance of innovating together.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Market Access 5 ways to address pricing and access challenges across the E... In the feature ‘Successfully navigating the complexity of market access across Europe to improve health equity’, originally published in the European Biopharmaceutical Review, EVERSANA Gene
Market Access Boehringer US head covers GLP-1s, PBMs, Trump at Reuters USA Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face